42 citations
,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
63 citations
,
July 2024 in “Journal of the American Academy of Dermatology” Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
8 citations
,
August 2016 in “Journal of the European Academy of Dermatology and Venereology” Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.
13 citations
,
November 2021 in “Pediatric Dermatology” Tofacitinib taken by mouth helps treat hair loss in children.
5 citations
,
July 2017 in “Skin appendage disorders” A man got a rare rash from the drug topiramate, which went away after he stopped taking it.
3 citations
,
September 2024 in “Dermatology and Therapy” Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.
January 2024 in “Faculty of 1000 Research Ltd” Tazarotene gel may be more effective for acne than adapalene gel.
March 2022 in “International Journal of Trichology” Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.
May 2025 in “Immunotherapy” Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.
4 citations
,
August 2010 in “Acta Biologica Hungarica” New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.
July 2025 in “Pakistan Journal of Intensive Care Medicine” Clobetasol propionate 0.05% ointment is more effective than tacrolimus 0.1% ointment for treating alopecia areata.
9 citations
,
October 2021 in “International Journal of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
1 citations
,
March 1997 in “Journal of Chromatography B: Biomedical Sciences and Applications” Researchers developed a method to measure different forms of a drug that could help treat prostate issues and hair loss, and found how these forms behave in animals.
January 2023 in “Cutaneous and Ocular Toxicology”
February 2013 in “Journal of The American Academy of Dermatology” Using hair loss drugs finasteride and dutasteride may cause sexual side effects.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
December 2021 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature”
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
17 citations
,
January 2021 in “Agrobiological Records” Allethrin caused harmful effects and organ damage in rats, worsening with higher doses and longer exposure.
23 citations
,
January 2012 in “International Food Research Journal” Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.
December 2022 in “Acta Ophthalmologica” Dutasteride potentially improves cell survival and reduces retinal damage in retinitis pigmentosa.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
37 citations
,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
54 citations
,
September 2019 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
March 2025 in “NATIONS UNIVERSITY INTERNATIONAL JOURNAL OF MULTI-DISCIPLINARY STUDIES” Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.
March 2019 in “Reactions Weekly”